

Cumulative Index 1991

Volume 11

March	LABORATORY AND HOSPITAL INFORMATION SYSTEMS, pages 1-270
June	VALUE AND LIMITATIONS OF CYTOLOGIC EXAMINATIONS, pages 271-508
September	LABORATORY TESTING IN ORGAN TRANSPLANTATION, pages 509-810
December	DIAGNOSIS OF IMPORTANT PARASITIC DISEASES, pages 811-1089

Note: Page numbers for complete issues and articles appear in **boldface** type.

- ABEL expert system, 145
ABO blood group incompatibility, in graft rejection, 538, 544, 592
Abscess, amebic, 849-850
 cytology in, breast, 358-359
 head and neck, 334
 liver, 343
 lung, 311
Acanthamoeba, in dermatitis, 871
 in granulomatous encephalitis, 861-866
 in keratitis, 870-871
 in pneumonitis, 871
Accounting information systems for, 87-88, 166
Accreditation. See *Laboratory regulation*.
Acid-base electrolyte program (ABEL), 145
Acinar cell carcinoma, pancreatic, cytology in, 349
Acinic cell carcinoma, of salivary glands, cytology of, 329, 331
Acquired immunodeficiency syndrome, pulmonary cytology in, 295-296, 310-313
 toxoplasmosis in, 934-935
Acute-phase proteins, in liver graft rejection, 662
Acute tubular necrosis, urinary sediment cytology in, 745

- Adenocarcinoma, cytology in, bile duct, 338, 340
 cervical, 282-286
 colon, 424-429, 435
 effusion, 450-451
 endometrial, 286-289
 esophageal, 408-409
 extrauterine, 289-290
 gastric, 418-419
 in liver metastasis, 341
 lung, 301-306
 pancreatic, 345, 347
 prostate, 388-389, 391
 vs. adenoma, 435
Adenocarcinoma in situ, cervical, cytology in, 283-284
Adenoid cystic carcinoma, of salivary glands, cytology in, 329
Adenoma, cytology in, colon, 434-436
 gastric, 421-422
 hepatocellular, 340
 pancreatic, 351
 salivary glands, 326-327
 thyroid, 318-319
Affinity column-mediated immunoassay, in cyclosporine A monitoring, 678
African trypanosomiasis, 899-905
 clinical features of, 902
 epidemiology of, 901-902

- African trypanosomiasis (*Continued*)
 laboratory diagnosis of, 903-905
 late stage, 904-905
 organisms causing, 899, 901
 trypanotolerance in, 902-903
- Agglutination test. See also *Hemagglutination test*.
 direct, in leishmaniasis, 920
 in toxoplasmosis, 928-929
 immunosorbent, in toxoplasmosis, 930
 in trypanosomiasis, 903
 latex, in toxoplasmosis, 929
- Alkaline phosphatase levels, in liver graft monitoring, 658-659
- Alloantibodies. See also *Antibody(ies), in transplantation, donor-specific*.
 removal of, before transplantation, 544
 to HLA, anti-idiotypic-like, 633-652
 laboratory detection of, 640-642
 networks in, 637-640
 relevance of, 643-645
 T-cell regulation and, 646-647
 terminology of, 635-637
 cell panel for, 556-557
 characteristics of, 552-555
 crossmatching strategy and, 564-567
 screening interpretation of, 563-564
 screening procedures for, 555-562
 screening strategy for, 562-563
- Alloantigens, presensitization to, 543-544
 T-cell receptor recognition of, 540-541
 T-cell response to, in graft rejection, 539-540
- Allograft rejection. See *Graft rejection*.
- Alloimmunization. See also *Alloantibodies*.
 predictive testing in, 768-769
 to HLA, 551-570
 epitopes in, 552-555
 in crossmatch procedures, 607
 induction of, 552
 loss of, monitoring of, 643-644
 private epitopes in, 552-555
 public epitopes in, 552-555
- Amastigotes, visualization of, in leishmaniasis diagnosis, 912-917
- Amebas, free-living, 861-872
 in acanthamoebic infections, 870-871
 in granulomatous amebic encephalitis, 866-870
 in meningoencephalitis, 861-866
- Amebiasis, 829-859
 diagnosis of, antigen detection in, 853-854
 circulating immune complexes in, 853
 immunoglobulin M detection in, 853
 immunologic methods in, 850-852
 molecular technology in, 854
 specimen collection for, 831-832
 specimen concentration for, 840-842
 specimen preservation for, 832-836
- staining in, 838-839, 842-844
 temporary wet mounts in, 837-839
- epidemiology of, 830
- extraintestinal, 849-850
- of liver, 849-850
- parasite of (*Entamoeba histolytica*), 829-830
 cysts of, 829-830, 846-847
 hematophagous form of, 830
 in vitro cultivation of, 847-849
 morphology of, 844-847
 trophozoites of, 829-830, 844-846
- American trypanosomiasis, 905-908
- Amphotericin B, in amebic meningoencephalitis, 866
- Amylase, in pancreas graft rejection, 663
- ANA-BEL expert system, 145
- Anal intraepithelial neoplasia, cytology in, 430-431
- Analysis of Acid-Base Status by Evaluating Lisp system, 145
- Anaplastic carcinoma, thyroid, cytology in, 322
- Angiomyolipoma, renal, cytology in, 384
- Angiosarcoma, liver, cytology in, 340
- Animal pathogenicity tests, in free-living amebic infections, 865
- Anion exchange centrifugation test, in African trypanosomiasis, 904
- Anti-human-globulin-augmented cytotoxicity test, in crossmatching, 610
- Anti-idiotypic antibodies, definition of, 636-637
 development of, 638-640
 in alloimmunization. See under *Alloantibodies*.
 in pretransplant enhancement, 644-645
 laboratory detection of, 640-642
 nonsite-associated, 636
 posttransplant, 589, 591-592
 site-associated, 636
 testing for, 578-579
 to OKT3, development of, 700-703
- Anti-isotype antibodies, to OKT3, development of, 702-703
- Anti-mouse immunoglobulin G antibodies, interference with OKT3 assays, 768
- Anti-OKT3 antibodies, development of, 700-703
- Antibody(ies), in transplantation, donor-specific, 571-602
 anti-Cw-induced rejection, 581
 anti-idiotypic, 578-579, 589
 autolymphocytotoxic, 588
 definition of, 572
 endothelial antigen system in, 576-578, 587-588
 epithelial antigen system in, 576-578
 in hyperacute rejection, 581

- in predicting positive crossmatches, 579–580
 induction of, 571–572
 low-affinity, 588, 592
 management of highly sensitized patients in, 582–583
 monocyte expression of, 576–578
 of heart, 585–589
 of kidney, 573–585
 of liver, 590–593
 of pancreas, 593–595
 poor match consequences and, 580–581
 positive donor lymphocyte crossmatch in, 573–576, 585–587, 590–591, 593
 posttransplant, 581–582, 588–589, 591–592, 644
 removal of, 582
 repeat antigen mismatch and, 580
 suppression of, 582 pretransplant transfusions in, 633–634, 644–645
 to *Giardia*, 821–823
 to non-HLA antigens. See under *Antigen(s), non-HLA*.
Antibody-dependent cell-mediated cytotoxicity test, in kidney graft monitoring, 737
Antibody detection tests, in cysticercosis, 1018
 in filariasis, 994–996, 998, 1002, 1005
 in pneumocystosis, 970
Antigen(s), HLA. See *HLA*.
 non-HLA, antibodies to, 621–632
 clinical significance of, 629
 gamma interferon effects on, 627
 in B cells, 628
 in endothelial cells, 622–624, 626
 in graft rejection, 622
 in keratinocytes, 626–627
 in monocytes, 624, 627–628
 skin crossmatching and, 625
 characteristics of, 628–629
 prior mismatch of, graft survival and, 580
 to *Entamoeba*, detection of, 853–854
Antigen detection tests, in cysticercosis, 1017
 in filariasis, 999–1000, 1005
 in free-living amebic infections, 864
 in pneumocystosis, 970–971
 in toxoplasmosis, 931
Antigen-presenting cells, allogeneic, in graft rejection, 539–540
Antigen-trapping ELISA technique, in African trypanosomiasis, 903
Antiglobulin-augmented complement-dependent cytotoxicity assay, in anti-idiotypic antibody detection, 641–642
 in HLA alloantibody screening, 555–556, 559–562
Apocrine carcinoma, breast, cytology in, 367
Asbestos bodies, in pulmonary cytology, 313
Aspergillosis, pulmonary cytology in, 312
Aspiration, needle. See *Needle aspiration*.
Atherosclerosis, in heart graft, 589
Australia, laboratory regulation in, 777–791
 accreditation authorities for, 781–784
 Commonwealth Department of Community Services and Health in, 781–782
 education authorities in, 788–790
 history of, 778–779
 inspecting authorities in, 786–788
 National Pathology Accreditation Advisory Council in, 779–781
 payment authorities in, 784–786
 quality assurance program authorities in, 788
 staff qualifications and, 783–784
 standards authorities for, 779–781
 Victorian Pathology Services Accreditation Board in, 782–783
Australian Association of Clinical Biochemists, 789
Australian Institute of Medical Laboratory Scientists, 789
Australian Society for Microbiology, 790
Autoantibodies, adsorption of, in crossmatch procedures, 608
Autoimmunization, to HLA, in crossmatch procedures, 607
Autolymphocytotoxic antibodies, in crossmatch procedures, 607–608
 in heart transplantation, 588
Automation, information systems in. See *Information systems*.

B cell(s), endothelial antigens expressed on, 628
 enrichment with, for crossmatch procedures, 606
Bacteremia, in liver transplantation, vs. rejection, 656
Bacterial infections, in transplant patients, 720
Bar codes, in information systems, 227–238
 applications of, 234–236
 barriers to, 236–237
 blood bank labelling with, 235
 clinical laboratory, 231–233
 industrial, 231
 patient identification with, 234–235
 readers for, 230–231
 standard structure for, 236–237
 symbology in, 228–229
Barrett's dysplasia, cytology in, 412–413

- Barrett's esophagus, cytology in, 407-408
 BASIC language, 30-31, 56
 Benign lymphoepithelial lesion, of salivary glands, cytology in, 331
 Beta-2-microglobulin, in liver graft rejection, 662
 Bethesda system, for gynecologic cytology, 273-279
 Bile cytology, in liver graft monitoring, 661
 Bile duct adenocarcinoma, cytology in, 338, 340
 Bilirubin levels, in liver graft monitoring, 658-659
 Billing, for hospital-based pathology services, 1052-1054, 1060-1061
 for hybrid laboratories, 161-166
 Biochemical diagnosis, of malaria, 951
 Biopsy, in graft monitoring, before OKT3 therapy, 707
 endomyocardial, 663-664, 742
 fine needle aspiration, 655-659, 663, 743-744
 liver, 655-659
 pancreas, 663
 in pneumocystosis diagnosis, 961, 963
 needle. See *Needle aspiration*.
 of leishmaniasis lesion, 916-917
 of skin, microfilariae detection in, 984-985
 BK papovavirus infection, in transplant patients, 721
 Bladder, tumors of, cytology in. See *Urinary cytology*.
 washing of, urine specimen from, 375
 Blood, in pulmonary cytology, 312-313
 lymphocyte isolation from, for transplantation crossmatching, 605
 Blood bank, bar code labelling in, 235
 Blood smear, stained, in filariasis diagnosis, 979-981
 Boeck and Drobhla's medium, for amebae cultivation, 848
 Branchial cleft cyst, cytology in, 334
 Breast lesions, cytology of, 357-368
 benign, 359-362
 malignant, 362-367
 metastasis to liver, 341
 nonneoplastic, 358-359
 technique for, 357
 vs. normal tissue, 358
 Bronchial atypia, vs. adenocarcinoma, 303-306
 Bronchial brushings/washings, for cytology, 295
 Bronchiectasis, cytology in, 311
 Bronchiolar carcinoma, cytology in, 301-306
 Bronchitis, cytology in, 311
 Bronchoalveolar lavage, cytology of, 295-296
 in lung graft monitoring, 664-665
 in pneumocystosis diagnosis, 961
Brugia malayi infection. See *Filariasis*.
 Brush cytology, bronchial, 295
 in colon adenocarcinoma, 425-429
 in gynecology, 273
 in ulcerative colitis, 432-433
 Burkitt's lymphoma, cytology in, 481-482
 C-dependent cytotoxicity assay, 555-556, 609-610, 737
 C language, 59, 62, 69
 Candidiasis, esophageal, cytology in, 404
 in transplant patients, 724
 Carcinoid tumors, of stomach, cytology in, 422-423
 Carcinoma. See also *Adenocarcinoma*.
 acinar cell, cytology in, 349
 acinic cell, cytology in, 329, 331
 adenoid cystic, cytology in, 329
 anaplastic, of thyroid, cytology in, 322
 apocrine, cytology in, 367
 breast, cytology in, 362-367
 bronchiolar, cytology in, 301-306
 colon, metastasis to liver, 341
 cyst-containing, cytology in, 334
 effusions in, 448-454
 follicular, of thyroid, cytology in, 319
 hepatocellular, cytology in, 337-338
 large-cell. See *Large-cell carcinoma*.
 lung. See *Pulmonary cytology*.
 medullary. See *Medullary carcinoma*.
 metastatic, cytology in, to liver, 340-342
 to neck lymph nodes, 334
 mucinous, cytology in, 367
 mucoepidermoid, cytology in, 327, 329
 oat-cell. See *Small-cell carcinoma*.
 pancreatic, cytology in, 349-351
 papillary. See *Papillary carcinoma*.
 renal cell, cytology in, 382, 384, 386
 signet-ring, cytology in, 451
 squamous cell. See *Squamous cell carcinoma*.
 thyroid, cytology in, 319-322
 transitional cell, urinary cytology in, 377, 381
 undifferentiated, cytology in, effusion, 454
 esophageal, 414
 urinary tract. See *Urinary cytology*.
 Carcinoma in situ, cytology in, bladder, 373, 376
 cervical, 277, 279
 Card agglutination trypanosomiasis test, 903
 Carotid body paraganglioma, cytology in, 333
 Catheterization, urine specimen from, 375
 Cavernous hemangioma, of liver, cytology in, 340
 CD cells. See under *Lymphocyte(s)*.

- Cell-mediated lympholysis, in HLA typing, 514, 544
- Cellophane tape test, in cysticercosis, 1019
- Centrifugation, in African trypanosomiasis diagnosis, 904
- in filariasis diagnosis, 981
 - in malaria diagnosis, 950–951
- Cerebrospinal fluid examination, in African trypanosomiasis, 904–905
- in cysticercosis, 1016–1018
 - in granulomatous amebic encephalitis, 867–868
- Cervical disorders, cytology in,
- adenocarcinoma, 282–286
 - carcinoma in situ, 277, 279
 - human papillomavirus lesions, 281–282
 - small-cell carcinoma, 279–280
 - squamous cell carcinoma, 280–282
- Cervical epithelial lesions, microinvasive squamous cell carcinoma, 280
- preneoplastic/early neoplastic, 273–280
- classification of, 275–276
 - cytologic features of, 277, 279
 - cytoplasmic differentiation of, 279–280
 - histopathology of, 276–277
 - keratinization of, 279
- Cervical intraepithelial neoplasia classification system, 276
- Cervicovaginal cytology. See *Gynecologic cytology*.
- Chagas disease, 905–908
- Chemiluminescence immunoassay, in cyclosporine A monitoring, 678
- Chemotherapy, cell changes in, bladder, 380
- esophagus, 411–412
 - prostate, 392
- Chlamydial infection, cytology in, 282
- Chloroma, cytology in, 488–489
- Cholangiocarcinoma, cytology in, 338, 340
- Cholestasis, in liver graft, vs. rejection, 658
- Chromatography, high performance liquid, in cyclosporine A monitoring, 675–676
- Chromium-release assays, in transplantation crossmatching, 615
- Circulating immune complexes, in transplantation, 579
- Cirrhosis, cytology in, 343
- CLAS expert system, 148
- COBOL, 7, 30–31, 56, 68–69
- Codes, bar. See *Bar codes*.
- for pathology services billing, 1057–1060
- Colitis, cytology in, cytomegalovirus, 429–430
- ulcerative, 431–434
- Colloid goiter, cytology in, 318
- Colon disorders, cytology in, 424–436
- adenocarcinoma, 424–429
 - metastatic to lung, 301–303
 - adenoma, 434–436
- anal intraepithelial neoplasia, 430–431
- carcinoma, metastatic to liver, 341
- cytomegalovirus colitis, 429–430
- Kaposi's sarcoma, 436
- ulcerative colitis, 431–434
- Commercialism, in laboratory regulation, 800–801
- Commonwealth Department of Community Services and Health Accreditation Branch (Australia), 781–782
- Communication, in information systems. See under *Information systems*.
- Competitors, of hospital laboratories. See under *Hospital laboratories*.
- Complement, in kidney graft rejection, 737
- Complement-dependent cytotoxicity assay, in anti-idiotypic antibody detection, 641–642
- in kidney graft monitoring, 737
 - in transplantation crossmatching, 609–610
- Complement factor analysis, expert systems for, 145–146
- Complement fixation test, in American trypanosomiasis, 906
- in toxoplasmosis, 928
- Computed tomography, in cysticercosis, 1015
- Computerized Laboratory Alerting System (CLAS), 148
- Computers, acquisition of, 1–20
- general principles of, 1–7
 - vendor selection in, 21–39
- aversion to, 49
- compilers in, 6–7, 56
- components of, 54–55
- dialogue with, 17
- display features of, 14–15, 131–132
- error messages of, 16
- flexibility of, 13–14
- friendliness of, 13–14
- graphical user interface in, 126–128
- hardware risks in, 30
- in workstations. See *Information systems, workstations for*.
- input devices for, 126
- interpreters in, 56
- life cycle of, 6–7
- maintenance of, 37–38, 48
- output devices for, 126
- performance limits of, 70–71
- personal, languages for, 59–60
- learning from, 2–3
- programming languages for. See *Languages, programming*.
- reliability of, 15
- requirements of, 13–17
- software for. See *Software*.
- strengths of, 3–5
- user interface of, 126–128
- weaknesses of, 3–5

- Computers (*Continued*)
 windowing systems in, 127-128
- Concavalin A test, in kidney graft monitoring, 738
- Concentration procedures, for filariasis diagnosis, 981-984
 for stool specimen, 819, 840-844, 884
- Condylomata, human papillomavirus, cytology in, 281-282
- Consultation, for information systems, 8-9
- Contract, for information system acquisition, 34-39
 for pathology services, 1052
- Coproantigen detection, in cysticercosis, 1020
- Costs, of information systems. See under *Information systems*.
- Cough induction, for sputum cytology, 294
- Counterimmunoelectrophoresis, in
 American trypanosomiasis, 906-907
 in giardiasis, 822
- Crossmatch procedures, in transplantation, 603-620, 766-767. See also *Mismatch*.
 chromium-release assays in, 615
 clinical relevance of, 615-617
 complement-dependent cytotoxicity assays in, 609-610
 donor-specific antibodies and, 573-576, 579-580
 flow cytometry in, 610-615
 historical aspects of, 604
 HLA typing, 734-735
 in HLA alloimmunization, 564-567
 negative results in, early allograft rejection in, 622
 positive results in, vs. hyperacute rejection, 586-587
 practical considerations for, 541-542
 recipient sera for, 607-608
 skin samples for, 625-629
 target cell isolation in, 604-606
- Crossreactivity, of HLA class I, 516-517
- Cryptococcosis, in transplant patients, 725
- Cryptosporidiosis, 873-897
 clinical features of, 882-883
 diagnosis of, histologic, 883
 laboratory, 883-887
 epidemiology of, 878-881
 etiologic agent of, 876-878
 in HIV-infected persons, 881
 parasite of, life cycle of, 876-878
 sources of, 880
 taxonomic relationships of, 876
 prevalence of, 880-881
 transmission of, 878-880
 treatment of, 887-889
- Culture, of *Entamoeba histolytica*, 848-849
 of *Leishmania*, 917-919
- Cyclophosphamide, in OKT3 therapy, 709
- Cyclosporine A monitoring, in transplantation, 671-691
 affinity column-mediated immunoassay in, 678
 area under curve, 686-687
 chemiluminescence immunoassay in, 678
 dilemmas in, 672-674
 enzyme-multiplied immunoassay in, 678
 fluorescence polarization immunoassay in, 677-678
 high performance liquid chromatography in, 675-676
- lymphokine assay in, 752, 754, 756-757
- metabolite interference in, 673-674
- methods for, 674-678
 correlations among, 684
 pharmacokinetics in, 686-687
 radioimmunoassay in, 674-677
 sample matrix for, 672-673
 trough, 686
 urinary sediment cytology in, 745-749
- Cyst(s), *Entamoeba*, 829-830, 847-848
Giardia, 813, 816
- Cystadenoma, serous, of pancreas, cytology in, 351
- Cystic lesions, cytology in, breast, 359
 liver echinococcus cyst, 343
 neck, 334
 pancreas, 351
 renal, 384-385
- Cysticercosis, 1011-1028
 clinical diagnosis of, 1014-1015
 epidemiology of, 1012, 1014
 laboratory diagnosis of, fecal examination in, 1018-1020
 future prospects for, 1023
 immunologic, 1015-1018
 lumbar puncture in, 1018
 parasite of, 1011-1012, 1014
 pathogenesis of, 1012
 public health aspects of, 1022-1023
 radiologic diagnosis of, 1015
 tissue diagnosis of, 1020-1021
 transmission of, 1011-1012
 treatment of, 1021-1022
- Cystosarcoma phyllodes, of breast, cytology in, 360
- Cystoscopy, urine specimen from, 375
- Cytobrush, in gynecologic cytology, 273
- Cytotoxicologic monitoring, of heart graft, 664, 742-743
- Cytology, breast, 357-368
 bronchial, 295
 bronchoalveolar lavage, 295-296
 cervicovaginal, 271-292
 colon, 424-436
 effusion, 443-467
 esophageal, 404-415
 gastrointestinal, 403-441

- genitourinary, 369-401
gynecologic, 271-292
head and neck tumors, 317-336
in graft monitoring, bile, 661
 exfoliative, 743-744
 pancreatic juice, 663
 urinary sediment, 744-749
in leukemia, 469-499
in lymphoma, 469-499
kidney, 381-387
liver, 336-344
needle aspiration in. See *Needle aspiration*.
pancreas, 344-352
prostate, 387-393
pulmonary, 293-315
salivary glands, 325-332, 334
sputum, 294-295
stomach, 415-424
testis, 393-394
thyroid, 317-324, 334
urinary, 369-381
- Cytomegalovirus infection, cytology in,
 colitis, 429-430
 pulmonary, 311
in transplant patients, 716-718, 720-722,
 725, 728-729
liver, vs. rejection, 657, 660-661
lymphokine assay in, 750-752
- D'Antoni's iodine, in amebiasis diagnosis, 838-839
- Data base, access to, 129-130
 centralized, 223-224
- Data management. See *Information systems*.
- Decision-oriented test request forms, 255-265
- Degenerative changes, in liver graft, 658
- Delta checking, in information systems, 100-101
- Density gradient separation, in lymphocyte isolation, for crossmatch procedures, 605
- Dermatitis, *Acanthamoeba* in, 870
- Diarrhea, in cryptosporidiosis, 882-883
- Dientamoeba fragilis*, 829, 843, 845, 847
- Direct agglutination test, in leishmaniasis, 920
 in toxoplasmosis, 928-929
- DNA probes, in amebiasis, 854
- Donor-specific antibodies. See under *Antibody(ies)*.
- Dot blot analysis, in HLA analysis, 515
- Dyskeratocytes, in cervical lesions, 281
- Dyslipoproteinemia, expert systems for, 145
- Dysplasia/carcinoma in situ classification, of cervical lesions, 276
- E-M antigens, in transplantation testing, 577-578
 early studies of, 622-624
- E-mail, in result reporting, 243-244
- Echinococcus cyst, liver, cytology in, 343
- Education, in laboratory accreditation, 788-790
- Effusion cytology, 443-467
 diagnostic accuracy of, 444-445
 in adenocarcinoma, 450-451
 in extramedullary hematopoiesis, 462
 in infections, 462
 in leukemia, 454-456
 in lymphoma, 454-456, 460
 in malignancy, 448-457
 in melanoma, 457
 in mesothelial hyperplasia, 446-448
 in mesothelioma, 448, 457-460
 in poorly differentiated malignancy, 460-461
 in primary site prediction, 461-462
 in rheumatoid disease, 462
 in sarcoma, 456-457, 460
 in small-cell carcinoma, 451, 454
 in squamous cell carcinoma, 451
 in trauma, 463
 in undifferentiated large-cell carcinoma, 454
 preparatory methods for, 443-444
- Eggs, detection of, in cysticercosis, 1018-1020
- Electron microscopy, in free-living amebic infections, 864-865, 869
- Electronic systems. See *Computers; Information systems*.
- Electrophoresis, gel. See *Gel electrophoresis*.
- ELISA. See *Enzyme-linked immunosorbent assay*.
- Encephalitis, amebic, from *Naegleria fowleri*, 861-866
 granulomatous, 866-870
 toxoplasmic, 934-935
- Endocervical adenocarcinoma, cytology in, 282-286
- Endocervical dysplasia, cytology in, 283-284
- Endocervical smears, sampling for, 273
- Endolimax nana*, 829, 845
- Endometrium, adenocarcinoma of, cytology in, 286-289
 hyperplasia of, cytology in, 286-287
 out-of-phase cells in, 287
 smear sampling from, 273
- Endomyocardial biopsy, in heart graft monitoring, 663-664, 742
- Endoscopic retrograde pancreatography, cytologic specimens from, 344-345
- Endothelial antigens, antibodies to, in heart transplantation, 587-588
 characteristics of, 628-629

- Endothelial antigens (Continued)**
 in transplantation testing, 576-578
 early studies of, 622-624
 skin crossmatch procedures for, 625-629
- Entamoeba coli*, 829, 838, 843, 844, 847
- Entamoeba hartmanni*, 829, 837-838, 844-847
- Entamoeba histolytica*. See *Amebiasis, parasite of*.
- Entamoeba polecki*, 829, 845-847
- Enzyme immunoassay**, in American trypanosomiasis, 907
 in toxoplasmosis, 929-930
- Enzyme-linked immunoelectrotransfer blot test**, in cysticercosis, 1016-1017
 in schistosomiasis, 1034-1035
- Enzyme-linked immunosorbent assay (ELISA)**, Falcon assay screening test (FAST), in schistosomiasis, 1031-1034
 in amebiasis, 852-854
 in anti-OKT3 antibody detection, 707-708
 in cysticercosis, 1016
 in filariasis, 995, 998
 in giardiasis, 821-823
 in leishmaniasis, 919-920
 in toxoplasmosis, 929
- Enzyme-multiplied immunoassay**, in cyclosporine A monitoring, 678
- Eosinophilia**, in liver graft rejection, 662
- Epithelial antigens**, in transplantation testing, 576-578
- Epithelial repair**, cytology in, in esophageal inflammation, 406-407
 in stomach inflammation, 415-417
- Epitopes**, private, in HLA alloimmunization, 552-555
 public, in HLA alloimmunization, 552-555
- Epstein-Barr virus infection**, in transplant patients, 717-718, 721-722, 727
- Erythropoietin**, in donor-specific antibody development prevention, 582
- Esophageal disorders**, cytology in, 404-415
 adenocarcinoma, 408-409
 Barrett's dysplasia, 412-413
 Barrett's esophagus, 407-408
 candidiasis, 404
 chemotherapy injury, 411-412
 epithelial repair, 406-407
 gastroesophageal reflux, 406-407, 414-415
 herpes esophagitis, 404-406
 pemphigus vulgaris, 414
 radiation esophagitis, 411-412
 squamous cell carcinoma, 409-410
 squamous cell dysplasia, 413-414
 undifferentiated carcinoma, 414
- ESPRE expert system**, 142
- Exfoliative cytology**, in transplant recipient monitoring, 743-744
- EXPERT expert system**, 138, 142
- Expert systems**, in laboratory information system, 135-151
- Eye**, toxoplasmosis manifestations in, 925, 934
- FAB classification**, of leukemia, 473-475
- Falcon assay screening test (FAST) enzyme-linked immunosorbent assay**, in schistosomiasis, 1031-1034
- Fat necrosis**, of breast, cytology in, 358
- Fecal specimen**. See *Stool examination*.
- Fibroadenoma**, of breast, cytology in, 360
- Fibrocystic mastopathy**, cytology in, 359
- Filarisis**, diagnosis of, 977-1010
 approaches to, 1005-1007
 immunologic, 993-1001
 antibody detection in, 994-995, 998, 1002, 1005
 antigen detection in, 999-1000, 1005
 molecular probes in, 1000
 lymphatic type, 994-995, 998-1000
 onchocerciasis, 1001-1002, 1005
 parasitologic, 978-991
 bloodborne microfilariae detection in, 979-981
 centrifugal concentration in, 981
 identification methods in, 985, 988, 991
 membrane filtration concentration in, 981-984
 skin microfilariae detection in, 984-985
 specimen collection for, 978-979
 stained blood smear in, 979
- parasites of**, 977-978
 morphology of, 985, 988, 991
- Fine needle aspiration biopsy**. See *Needle aspiration*.
- Flotation techniques**, for fecal specimen concentration, 841-843
- Flow cytometry**, in free OKT3 antibody detection, 706
 in graft monitoring, 739-740, 742-743
 in leukemia/lymphoma cytology, 475. See also specific type under *Lymphoma* and *Leukemia*.
 in malaria diagnosis, 949-950
 in T-cell detection, in OKT3 therapy, 704-706
 in transplantation crossmatching, 610-615
 in urinary cytology, 381
- Fluorescence activated cell sorter**, in graft monitoring, 739-740
- Fluorescence polarization immunoassay**, in cyclosporine A monitoring, 677-678

- Fluorescent microscopy, in malaria diagnosis, 947-948
- Focal nodular hyperplasia, of liver, cytology in, 340
- Follicular adenoma, thyroid, cytology in, 318-319
- Follicular carcinoma, thyroid, cytology in, 319
- Formalin-ether sedimentation technique, for fecal specimen concentration, 841
- Formalin solutions, for stool specimens, 835-836
- FORTRAN, 6-7, 30-31, 56, 68-69
- Free antibody test, in OKT3 therapy, 706
- Fungal infections, cytology in, esophageal, 404
pulmonary, 311-312
in transplant patients, 724
- Gamma interferon, in endothelial antigen studies, 627
- Gastrinoma, cytology in, 350-351
- Gastritis, cytology in, 415-416, 420, 423-424
- Gastroesophageal reflux, cytology in, 406-407, 414-415
- Gastrointestinal cytology, 403-441
esophagus, 404-415
large intestine, 424-436
stomach, 415-424
- Gel-diffusion precipitins, in amebiasis, 851-852
- Gel electrophoresis, in endothelial antigen characterization, 628-629
in HLA class I analysis, 514
one-dimensional isoelectric focusing, 518
- Genitourinary cytology, 369-401
prostate, 387-393
renal, 381-387
testis, 393-394
urinary, 369-381
- Germ cell tumors, testicular, cytology in, 393-394
- Giardiasis, 811-827
chronic, 818
clinical presentation of, 818
diagnosis of, 818-821
experimental approaches in, 823
immunologic methods in, 821-823
- epidemiology of, 816-818
- parasite of, antigens to, 822-823
biology of, 811-813
life cycle of, 816
morphology of, 813, 816
taxonomy of, 811-813
transmission of, 816-817
- Giems stain, in pneumocystosis diagnosis, 966
- Gleason grading, for prostate cancer, 388
- Glucagonoma, cytology in, 350-351
- Glycerol, for worm clearing, 1048-1049
- Goiter, cytology in, 318
- Government, in laboratory regulation, 795-800
- Graft rejection, ABO antigen effects on, 537-550
accelerated, heart, atherosclerosis in, 589
kidney, 585
- anti-idiotypic antibodies in. See *Anti-idiotypic antibodies*.
- crossmatching in, 766-768
- delayed hyperacute, kidney, 583, 585
- donor-specific antibodies in. See *Anti-body(ies), in transplantation, donor-specific*.
- histocompatibility matching in, 763-766
- HLA-Cw in, 581
- HLA influence on, 537-550
clinical matching techniques and, 541-543
immune recognition in, 539-540
immunogenic determinants of, 540-541
presensitization and, 543-544
- human monocyte antigen system in, 538
- hyperacute, heart, 586-587, 589
kidney, 583
- liver, 591, 593
- pancreas, 595
- immunosuppressive therapy monitoring in, 767-768
- monitoring of, 653-670
- exfoliative cytology in, 743-744
- fine needle aspiration biopsy in, 743-744
- heart, 663-664, 742-743
- heart-lung, 664-665
- kidney, 735-738, 744-749
urinary sediment cytology in, 744-749
- liver. See under *Liver transplantation*.
- lung, 664-665
- lymphocyte surface markers in, 739-741
- pancreas, 663
- non-HLA antigens in. See *Antigen(s), non-HLA*.
- OKT3 therapy in. See *OKT3 monoclonal antibodies*.
- pathology in, heart, 586-587, 589
kidney, 583, 585
liver, 591, 593
pancreas, 595
- therapy monitoring in, 693-714
- urinary sediment cytology in, 744-749
- vascular endothelial cell antigen system in, 538

- Graft rejection (*Continued*)
 with negative lymphocyte crossmatch, 622
- Granular cell tumor, of breast, cytology in, 360
- Granulocytic sarcoma, cytology in, 488–489
- Granuloma, liver, cytology in, 343
- Granulomatous amebic encephalitis, 866–869
- Granulomatous reactions, of lung, cytology in, 312
- Gynecologic cytology, 271–292
 Bethesda system for, 273–279
 combined cervicovaginal smear in, 272
 endocervical sampling in, 273, 283–284
 endometrial sampling in, 273
 in chlamydial infection, 282
 in endocervical adenocarcinoma, 282–286
 in endometrial lesions, 286–289
 in extrauterine adenocarcinoma, 289–290
 in human papillomavirus lesions, 281–282
 in inflammatory conditions, 280–282
 in squamous preneoplastic/early neoplastic lesions, 273–280
 sample adequacy for, 273
 techniques for, 272–273
 two-smear method for, 272
- V-C-E smears for, 272–273
- Gynecomastia, cytology in, 362
- Hashimoto's thyroiditis, cytology in, 323–324
- Head and neck tumors, cytology in, 317–336
 cystic lesions, 334–335
 metastasis, 334
 paraganglioma, 333
 salivary glands, 325–332
 schwannoma, 332–333
 soft-tissue, 336
 thyroid, 317–324, 334
- Health Industry Business Communications Council, bar code standards of, 236–237
- Health Level 7 Standard, for information systems, 223, 240
- "Heart failure cells," in pulmonary cytology, 312
- Heart-lung transplantation, graft monitoring in, 664–665
- Heart transplantation, donor-specific antibodies in, 585–589
 graft monitoring in, 663–664, 742–743
- Heidenhain's iron alum-hematoxylin, in amebiasis diagnosis, 843
- HELP system, 140
- Hemagglutination test, indirect, in amebiasis, 851
 in American trypanosomiasis, 906
 in toxoplasmosis, 928
- Hemangioma, cavernous, of liver, cytology in, 340
- Hematology, expert systems for, 144–145
- Hematopoiesis, extramedullary, effusion cytology in, 462
- Hematoxylin stain, for worms, 1049–1050
- Hemosiderin, in pulmonary cytology, 312–313
- Hepatitis, in transplant patients, 657, 660, 718, 723, 727
- Hepatocellular adenoma, cytology in, 340
- Hepatocellular carcinoma, cytology in, 337–338
- Hepatocytes, cytology of, 337
- Herpes simplex virus infections, in transplant patients, 717, 721–722
- Herpes virus infections, cytology in, esophageal, 404–406
 pulmonary, 311
- Herpesvirus type 6 infection, in transplant patients, 717, 720
- High performance liquid chromatography, in cyclosporine A monitoring, 675–676
- Histiocytic infiltration, of stomach, cytology in, 420
- Histologic studies, in cryptosporidiosis, 883
- HIV infection. See *Human immunodeficiency virus infection*.
- HLA, 509–536
 alloimmunization to. See under *Alloimmunization*.
 antibodies to. See also *Antibody(ies), in transplantation, donor-specific*.
 posttransplant, 588–599
 class I, cellular subtypes of, 518
 crossreactivity of, 516–517
 functions of, 511
 in kidney graft rejection, 736
 in liver graft rejection, 660, 662
 polymorphisms of, definitions of, 515–522
 structural basis for, 519–522
 private antigen detection in, 517–518
 soluble, interference with anti-idiotypic antibody detection, 642
 structure of, 510
 typing of, 512–513
 class II, functions of, 511
 in liver graft rejection, 660
 polymorphisms of, definitions of, 522–531
 structural basis for, 529–531
 structure of, 510–511
 typing of, 513
 genetic basis of, 510–512
 genotyping of, 542
 haplotyping of, 542–543
 mismatching of. See *Mismatch, in transplantation*.
 polymorphisms of. See also specific class.

- definitions of, class I, 515-522
 class II, 522-533
 determination of, 512-515
 biochemical methods for, 514
 cellular typing in, 513-514
 class I typing in, 512-513
 class II typing in, 513
 molecular typing in, 515, 518-519
 serology in, 512
 presensitization to, 543-544
 typing of, 512-513, 515, 518-519, 542-543, 734-735, 763-766
- HLA-Cw, in graft rejection, 581
- HLA-D alleles, molecular designation of, 528-529
- HLA-DQ, HLA-DRB associations of, 528
- HLA-DR, HLA-Dw associations of, 525
- HLA-DRB, HLA-DQ associations of, 528
- HLA-Dw, HLA-DR associations of, 525
- Hodgkin's disease, cytology in, 488-489
 effusion, 460
- Home monitoring, data management in, 245
- Hospital laboratories, competitors of,
 information system advantages over, 187-202
 organizational changes as response to, 200-201
 types of, 188-190
 quality of, 190-192
 services of, information systems in, 194-200
 users of, 192-194
- Human immunodeficiency virus infection, cryptosporidiosis with, 881-883
 in transplant patients, 718, 727-728
- Human lymphocyte/leukocyte antigen. See *HLA*.
- Human monocyte antigen system, 538, 624
- Human papillomavirus lesions, cervical, cytology in, 281-282
- Hürthle cells, in thyroid nodules, 321, 323
- Hybrid laboratories, information systems
 for, 45-46, 153-169
 billing in, 161-166
 client-specific requirements in, 167-168
 in patient identification/tracking, 155-156
 in specimen identification/tracking, 156-157
 laboratory growth and, 154-155
 operations in, 157-161
 reporting considerations in, 158-161
- Idiotypes. See also *Anti-idiotypic antibodies*.
 crossreactive, 636
 networks of, 637-640
 public, 636
 regulatory, 636
- terminology of, 635-636
- Ileal conduit, urine specimen from, 375
- Immune complexes, circulating, in
 amebiasis, 853
 in transplantation, 579
- Immunoassay, in cyclosporine A monitoring,
 affinity column-mediated, 678
 chemiluminescence, 678
 enzyme-multiplied, 678
 fluorescence polarization, 677-678
- Immunoblastic lymphoma/sarcoma, cytology in, 483-484
- Immunodeficiency, cryptosporidiosis in, 881-883
 toxoplasmosis in, 934-935
- Immunodiagnosis, of African
 trypanosomiasis, 903
 of amebiasis, 850-852
 of American trypanosomiasis, 906
 of cysticercosis, 1015-1018
 of giardiasis, 821-823
 of malaria, 948-949
 of pneumocystosis, 970-971
- Immunoelectrophoresis, in American
 trypanosomiasis, 906-907
- Immunofluorescence assay, in endothelial
 crossmatch techniques, 624-625, 628-629
 in giardiasis, 821-822
 indirect, in amebiasis, 851
 in free-living amebic infections, 865
- Immunofluorescent antibody test, in African
 trypanosomiasis, 903
 in American trypanosomiasis, 906
- Immunofluorescent stain, in pneumocystosis
 diagnosis, 970
- Immunoglobulin A, detection of, in
 toxoplasmosis, 935
- Immunoglobulin M, antiepithelial, 578
 detection of, in African trypanosomiasis, 905
 in amebiasis, 853
 in giardiasis, 821
 in toxoplasmosis, 929-931
 reactivity of, elimination of, in recipient
 serum preparation, 608
 removal of, before transplantation, 573
- Immunohistochemistry, in liver graft
 monitoring, 659-661
- Immunologic interventions, in
 cryptosporidiosis, 888-889
- Immunoperoxidase stain, in pneumocystosis
 diagnosis, 970
- Immunophenotyping, in leukemia/
 lymphoma cytology, 474-475. See also
 specific type under *Lymphoma* and
Leukemia.
- Immunosorbent agglutination test, in
 toxoplasmosis, 930

- Immunosuppressive drugs. See also *Cyclosporine A; OKT3 monoclonal antibodies.*
 in transplantation, 735
 infections and, 716-717
 monitoring of, 767-768
- Imprint sampling, from leishmaniasis lesion, 914
- Indirect fluorescent antibody test, in filariasis, 995
 in leishmaniasis, 920
 in toxoplasmosis, 929-930
- Indirect hemagglutination test, in amebiasis, 851
 in American trypanosomiasis, 906
 in toxoplasmosis, 928
- Indirect immunofluorescence test, in amebiasis, 851
- Infant, toxoplasmosis diagnosis in, 933-934
- Infection, cytology in, bladder, 380
 effusion, 462-463
 lung, 295-296, 310-313
 in transplant patients, 715-731
 graft-versus-host reactions in, 717
 immunosuppressive drugs and, 716-717
 laboratory evaluation of, approach to, 723-725
 types of, 722-723
 viruses, 725-729
 organ type and, 716
 pathogen sources in, 717-719
 pathogen types in, 719-721
 pretransplant samples in, 722
 risk factors in, 715-717
 vs. rejection, 656-657
- Infertility, male, testicular biopsy in, 394
- Inflammation, cytology in, bladder, 380
 esophageal, 406-407
 gastric, 415-417
- Information systems, accessioning in, 98
 accounting functions in, 87-88, 166
 acquisition of, background information for, 9-11
 issues in, 1-20
 vendor selection for, 21-39
 bar codes in, 227-238
 billing functions of, 161-166
 caveats in, 118, 120
 check digit in, 87-88
 communication in, 5-6, 46, 49-50
 of test results, 184
 peer-to-peer, 244
 standards for, 222-223
 to physician, 243-244
 competitive advantages of, 187-202
 computers in. See *Computers.*
 consultation in, 8-9
 contract for, 34-39
 cost-benefits model for, 118
 costs of, 105-106
- external, 112
 internal, 112-114
 savings in, 114-117
- data base access with, 129-130
 data base centralization in, 223-224
 data retrieval from, 217
 data verification in, 99-100, 143-144
 delta checking in, 100-101
 design of, 83-104
 patient-centered, 214-218
 efficiency of, 108
 errors in, 66-70
 evolution of, 73-81
 expert systems in, 135-150
 fault tolerance in, 217
 for first-time buyer, 107
 for hybrid laboratories. See under *Hybrid laboratories.*
 for nursing records, 206-208
 for reference laboratory, 101-102
 combined with hospital laboratory. See *Hybrid laboratories.*
 history of, 73-81
 image reports in, 242-243
 implementation of, 41-51
 in-house development of, 32-33
 in scheduling, 215-216
 test results, 179
 information flow in, 12-13
 instrument interface in, 99-100
 invoice generation by, 165
 justification of, 105-121
 knowledge base in, 137-138, 146
 laboratory needs analysis for, 11-13
 leadership for, 8
 literature search on, 110
 medical record in, 209-211
 Medicare system impact on, 208-209
 multivendor type, 221-225
 networks in, connection of, 221-225
 disadvantages of, 211-214
 expert systems in, 140
 programming languages for, 60-61
 software for, 48-49
 workstation and, 125
 open architecture of, 221-225
 optimization of, 205-208
 order entry in, 96-97, 141-142
 order forms for, 255-265
 paperless, 217
 patient-centered, 203-220
 personnel selection for, 7-8
 physicians' offices interfaces in, 239-249
 printers for, 177-178, 229
 programming languages for. See *Languages, programming.*
 project management in, 102
 prospective analysis of, 110-118
 replacement of, 107-108
 reports in. See *Reports, of test results.*

- request for proposal for, 21–26
 result entry into, 98–99
 retrospective analysis of, 111–112
 scope of, 11–12
 security systems in, 159, 242
 selection of, 27–34
 specimen handling in, 142–143
 spreadsheets in, 60
 telecommunications in, 49–50
 training for, 49
 underconfiguration of, 47
 upgrading of, 38
 word processing in, 59–60
 workstations for, 70, 123–134, 183–184
 applications of, 128–131
 data display, 131–132
 hardware perspective in, 123–124
 productivity of, 129–130
 software for, 124–125
 user interface in, 126–128
- Inspection authorities, in Australia, 786–788
- Insulinoma, cytology in, 350–351
- Interleukin(s), in transplant recipient monitoring, 750–757
- Interleukin-2 receptors, in liver graft rejection, 662
- Intestinal metaplasia, in stomach, cytology in, 417–418
- Intestine, large. See *Colon*.
- Iodamoeba bütschlii*, 829, 845–847
- Iron hematoxylin, in amebiasis diagnosis, 843–844
- Islet cell tumors, cytology in, 350–351
- Isoenzyme analysis, in free-living amebic infections, 865
- Kaposi's sarcoma, of colon, cytology in, 436
- Keratinization, in cervical lesions, 279
- Keratinocytes, alloantigens in, 626–627
- Keratitis, *Acanthamoeba* in, 869–870
- Kidney transplantation, cytology in, 385–386
 donor-specific antibodies in, 573–585
 monitoring in, 735–738, 744–749
 non-HLA antigens in. See *Antigen(s), non-HLA*
- Kidney tumors, cytology in, 381–387
 angiomyolipoma, 384
 cysts, 384–385
 diagnostic value of, 385–386
 limitations of, 386
 oncocytoma, 384
 pathology in, 382–385
 renal cell carcinoma, 382, 384
 safety of, 386–387
 Wilm's, 384
- Knott procedure, for filariae concentration, 981
- Knowledge base, in laboratory information system, 137–138, 146
- Koilocytes, in cervical lesions, 281
- Laboratory information systems. See *Information systems*.
- Laboratory management, test requests in, decision-oriented, 255–265
- Laboratory regulation, historical aspects of, commercialism in, 800–801
 governmental role in, 795–800
 origins of, 793–795
 in Australia, 777–791
 pathology of, 793–802
- Lactophenol, for worm clearing, 1048–1049
- Languages, programming, 6–7, 30–31, 53–72
 combinatorial number problems in, 67–68
 effectiveness and, 64–66
 for networks, 60–61
 for personal computers, 59–60
 in top-down programming, 59, 66
 object-oriented, 61–62
 productivity and, 63–64
 prototype, 65–66
 simplicity in, 62–63
 structure of, 55–57, 62–64
 system robustness and, 66–70
 transparency in, 58
 variety of, 57–62
 vs. applications, 58–59
- Large-cell carcinoma, cytology in, effusion, 454
 lung, 309–310
- Large-cell lymphoma, cytology in, 484–485
- Large intestine. See *Colon*.
- Latex agglutination test, in toxoplasmosis, 929
- Lavage, for cytology, bronchoalveolar. See *Bronchoalveolar lavage*.
- colon, 425–427, 431–433
- Leiomyoblastoma, of stomach, cytology in, 424
- Leiomyosarcoma, metastatic to liver, cytology in, 342
- Leishmaniasis, diagnosis of, 909–922
 direct agglutination test in, 920
 enzyme-linked immunosorbent assay in, 919–920
 indirect fluorescent antibody test in, 920
- Montenegro skin test in, 919
 mucocutaneous, 911–919
 amastigote visualization in, 912–917
 lesion sampling in, 912–917
 organism isolation in, 917–919
 serologic, 919–920

- Leishmaniasis (Continued)**
visceral, 911
- Lennert's lymphoma**, cytology in, 495
- Leptomyxid amebas**, in granulomatous encephalitis, 866-870
- Leu monoclonal antibodies**, in CD3 cell detection, 705-706
in graft monitoring, 739-740
- Leukemia**, cytology in, 469-499
acute lymphoblastic, 487-488
chronic lymphocytic, 490-491
classification of, 473-475
effusion, 454-456, 460
granulocytic sarcoma and, 486-487
indications for, 471
monomorphic processes in, 477-478
multiparameter approach to, 471-472
nucleic acid flow cytometry in, 475
expert systems for, 145
- Lewis antigens**, in bladder cancer, 381
- Lipid pneumonia**, cytology in, 312
- Lipoma**, cytology in, breast, 359-360
head and neck, 336
- LIS**. See *Information systems*.
- Lithiasis, urinary**, cytology and, 380
- Liver**, amebic abscess of, 849-850
- Liver transplantation**, donor-specific antibodies in, 590-593
monitoring in, 654-662
bile cytology in, 661
biochemical markers in, 658-659
cellular methods in, 662
cholestasis in, 658
fine needle aspiration biopsy in, 655-659
immunohistochemistry in, 659-661
in acute rejection, 654-655
inflammation in, 655-657
liver enzyme levels in, 658-659
lymphocyte growth studies in, 661
needle biopsy in, 659
noninvasive, 661-662
parenchymal morphologic changes in, 658
soluble marker detection in, 662
- Liver tumors**, cytology in, 336-344
benign, 343
cavernous hemangioma, 340
cholangiocarcinoma, 338, 340
focal nodular hyperplasia, 340
hepatocellular adenoma, 340
hepatocellular carcinoma, 337-338
mesenchymal, 340
metastatic, 340-342
sarcoma, 340
vs. normal tissue, 337
vs. parenchymal disease, 343
- Loa loa* infection**. See *Filariasis*.
- Lobular carcinoma**, breast, cytology in, 365
- Locke-egg media**, for amebae cultivation, 847-848
- Lugol's stain**, in amebiasis diagnosis, 838-839
- Lumbar puncture**, in cysticercosis, 1018
- Lung disorders**, *Acanthamoeba* infection, 871
cytology in. See also *Pulmonary cytology*.
abscess, 311
adenocarcinoma, 301-306
carcinoma, 294-295, 454
needle aspiration in, 297-298
infections, 295-296, 310-313
large-cell carcinoma, 309-310
small-cell carcinoma, 306-309
squamous cell carcinoma, 298-300
vs. adenocarcinoma, 303
- Lung transplantation**, monitoring in, 664-665
- Lymph nodes**, filariasis of, diagnosis of, 994-995, 998-1000
lymphocyte isolation from, for transplantation crossmatching, 604
needle aspiration of. See *Lymphoma, cytology in*.
- of neck, metastasis to, cytology in, 334
- Lympho-Kwik reagent**, in lymphocyte isolation, for crossmatch procedures, 605
- Lymphoblastic leukemia**, acute, cytology in, 487-488
- Lymphoblastic lymphoma**, malignant, cytology in, 482-483
- Lymphocyte(s)**. See also *B cell(s); T cell(s)*.
blastogenesis of, in kidney graft monitoring, 738
- CD2**, in CD3 cell detection, 705
- CD3**, OKT3 monoclonal antibody reaction with, 693-695
- CD4**, in graft monitoring, 739-740
in heart graft monitoring, 742-743
- CD5**, in CD3 cell detection, 705
- CD8**, in graft monitoring, 739-740
in heart graft monitoring, 742-743
isolation of, for transplantation crossmatching, 604-606
- Lymphocyte-mediated cytotoxicity assay**, in kidney graft monitoring, 737
- Lymphocyte surface markers**, in transplant recipient monitoring, 739-741
- Lymphocyte tests**, in transplantation, 531-532, 661
antibodies missed by, 622
chromium-release assays in, 615
clinical relevance of, 615-617
complement-dependent cytotoxicity assays in, 609-610, 641-642, 737
flow cytometry in, 610-615
historical aspects of, 604
in heart graft monitoring, 742-743

- in HLA typing, 513-514
in kidney graft monitoring, 737-738
in liver graft monitoring, 662
recipient sera for, 607-608
target cell isolation in, 604-606
- Lymphocytic leukemia, chronic, cytology in, 490-491
- Lymphocytic lymphoma, cytology in, 490-491
- Lymphocytic thyroiditis, cytology in, 323-324
- Lymphoid infiltrates, of salivary glands, cytology in, 331
- Lymphokines, in transplant recipient monitoring, 750-757
- Lympholysis, cell-mediated, in HLA typing, 514, 544
- Lymphoma, cytology in, 469-499
classification of, 472-473
effusion, 454-456, 460
Hodgkin's disease, 460, 488-489
immunoblastic, 483-484
in partial node involvement, 496
indications for, 471
large-cell, 484-485
Lennert's, 495
malignant, 490-493
malignant lymphoblastic, 482-483
mixed-cell, 493-495
monomorphic processes in, 477-478
multiparameter approach in, 471-472
nucleic acid flow cytometry in, 475
salivary glands, 331
small cleaved-cell, 492-493
small lymphocytic plasmacytoid, 491-492
small noncleaved cell, 481-482
stomach, 419, 422
T-zone, 495
thyroid, 322-323
well-differentiated lymphocytic, 490-491
- Lymphoproliferative disorders, after transplantation, 721
- Magnetic immunobeads, in lymphocyte isolation for crossmatching, 605-606
- Magnetic resonance imaging, in cysticercosis, 1015
- Major histocompatibility complex. See *HLA*.
- Malaria, 941-956
clinical assessment of, 943
clinical symptoms of, 942-943
diagnosis of, biochemical, 951
centrifugal, 950-951
flow cytometry in, 949-950
fluorescent microscopy in, 947-948
immunologic methods in, 948-949
- laboratory procedures for, 951
microscopic, 943, 945-948
nucleic acid, 951-953
polarized light microscopy in, 947
specimen collection/preparation for, 945-947
- parasite of, 941
life cycle of, 942
risk factors for, 941
- Mancini method, in African trypanosomiasis diagnosis, 905
- Mansonella* infections. See *Filariasis*.
- Markers, for graft rejection, liver, 662
pancreas, 663
- Massachusetts General Hospital Utility Multi-Programming System (MUMPS), 7, 30-31, 57, 76, 86
- Mastitis, cytology in, 359
- Medical Electrophoresis Analysis Interactive Expert system, 144
- Medical record, problems with, 209-211
- Medicare, cost reimbursement system of, 208-209
- MEDLINE, access to, 129
- Medullary carcinoma, cytology in, breast, 365
thyroid, 321
- MEDX Standard, for information systems, 223, 240
- MELANIE expert system, 144
- Melanoma, cytology in, effusion, 457
metastatic to liver, 341-342
- Membrane filtration, as concentration method, in filariasis diagnosis, 981-984
- Meningoencephalitis, amebic, 861-866
- Merthiolate iodine formalin, for stool specimens, 835
- Mesothelial repair, cytology in, 446-448
- Mesothelioma, malignant, effusion cytology in, 448, 457-460
- Metastasis, cytology in, to liver, 340-342
to lung, 301-303
to neck lymph nodes, 334
- Methenamine silver nitrate stain, in pneumocystosis diagnosis, 965
- Methylene blue dye test, in toxoplasmosis, 928
- Microfilariae. See *Filariasis*.
- Microlymphocytotoxicity assay, in transplantation testing, 609-610
- Microscopy, in free-living amebic infections, 863-864, 868-869
in malaria diagnosis, 943, 945-948
- Millipore membranes, as concentration method, in filariasis diagnosis, 981-984
- Mini-anion exchange centrifugation test, in African trypanosomiasis, 904
- Minor histocompatibility antigens, in graft rejection, 622-624

- Mismatch, in transplantation, donor-specific antibodies and, 580
poor, results of, 580-581, 735
repeat antigen mismatch in, 580
selective, results of, 565
significance of, 542
zero, 532-533
- Mixed lymphocyte culture, in HLA typing, 513
in transplantation testing, 531-532
- Mixed lymphocyte reaction, sensitization detection by, 544
- Molecular technology, in amebiasis diagnosis, 854
in filariasis diagnosis, 1000
- Molecular typing, in HLA analysis, 515, 518-519
- Monoclonal antibodies, in American trypanosomiasis diagnosis, 907
in lymphocyte isolation, for crossmatch procedures, 606
in pneumocystosis diagnosis, 971
in transplant rejection. See under *OKT3 monoclonal antibodies*.
- Monocytes, endothelial antigens expressed on, 576-578, 624, 627-628
- Montenegro skin test, for leishmaniasis, 919
- Mott cells, in African trypanosomiasis, 904
- Mucinous carcinoma, breast, cytology in, 367
- Mucinous cystic neoplasm, of pancreas, cytology in, 351
- Mucocutaneous leishmaniasis. See under *Leishmaniasis*.
- Mucoepidermoid carcinoma, of salivary glands, cytology in, 327, 329
- Mucormycosis, pulmonary cytology in, 312
- MUMPS language, 7, 30-31, 57, 76, 86
- Mycoplasma infections, in transplant patients, 721
- Myocardium, biopsy of, in heart graft monitoring, 663-664, 742
- Naegleria fowleri*, in meningoencephalitis, 861-866
- National Association of Testing Authorities (Australia), 786-787
- National Pathology Accreditation Advisory Council (Australia), 779-780
- Neck tumors. See *Head and neck tumors*.
- Needle aspiration, in graft monitoring, 743-744
liver, 655-659
pancreas, 663
in leukemia. See *Leukemia, cytology in*.
in lymphoma. See *Lymphoma, cytology in*.
- in pulmonary cytology, 297-298
- of breast lesions, 357-368
- of carotid body paraganglioma, 333
- of cystic neck lesions, 334
- of effusions. See *Effusion cytology*.
- of kidney, 382-387
- of leishmaniasis lesion, 914
- of liver tumors, 336-344
- of pancreatic tumors, 344-352
- of prostate, 387-393
- of salivary glands, 325-332
- of schwannoma, 332-333
- of thyroid, 317-324
- Needle biopsy, in liver graft monitoring, 659
- Neuroendocrine tumors, of stomach, cytology in, 422-423
- Nodular goiter, cytology in, 318
- Nucleic acid flow cytometry, in leukemia/lymphoma cytology, 475. See also specific type under *Lymphoma* and *Leukemia*.
- Nucleic acid hybridization methods, in cytomegalovirus detection, 728
in filariasis diagnosis, 1000
in malaria diagnosis, 951-953
- Nursing, clerical work in, 206-208
- Nylon wool columns, in lymphocyte isolation, for crossmatch procedures, 606
- Oat-cell carcinoma. See *Small-cell carcinoma*.
- OKT3 monoclonal antibodies, in transplantation, 693-714
biopsy in, 707
dosage of, 695
first-dose reaction to, 696
free antibody measurement in, 706
immune response to, 700-703
control of, 709-710
in monitoring, 707-708
in acute rejection, 695
lymphokine assay in, 755-756
monitoring of, 704-709, 740-741
prophylactic, 695
- T-cell response to, 696-700, 704-706
target antigen on T cells, 693-695
- OKT8 monoclonal antibodies, in transplantation, monitoring of, 739-740
- Oligonucleotide probes, sequence-specific, in HLA analysis, 515
- Onchocerciasis, 1001-1002, 1005
- Oncocytoma, renal, cytology in, 384
- Oocysts, of *Cryptosporidium*, 876-878
atypical, 886-887
environmentally resistant, 878-880
laboratory examination of, 880-887
low numbers of, 886

- reservoirs for, 880
Open systems architecture, for information handling, 221-225
Opportunistic infections, pulmonary cytology in, 310-313
Ovarian cancer, cytology in, 289-290
OVERSEER expert system, 146
- Pancreas transplantation, donor-specific antibodies in, 593-595
monitoring in, 663
Pancreatic juice cytology, in graft monitoring, 663
Pancreatic tumors, cytology in, 344-352
 acinar cell carcinoma, 349
 cystic, 351
 ductal adenocarcinoma, 345, 347
 islet cell, 350-351
 papillary-cystic, 349-350
 vs. normal tissue, 345
 vs. pancreatitis, 351
 vs. pseudocyst, 351-352
Pancreatitis, cytology in, 351
Papillary carcinoma, cytology in, bladder, 370-372, 376-377, 380
thyroid, 319-321
Papillary cystadenoma lymphomatosum, of parotid, cytology in, 327
Papillary-cystic neoplasm, of pancreas, cytology in, 349-350
Papilloma, of breast ducts, cytology in, 362
Papillomavirus infection, in transplant patients, 728
Parabasal cells, atypical, in cervical lesions, 281-282
Paraganglioma, carotid body, cytology in, 333
Parasitic infections, acanthamoebic, 869-870
 African trypanosomiasis, 899-905
 amebiasis, 829-859
 from free-living organisms, 861-872
 amebic meningoencephalitis, 861-866
 American trypanosomiasis, 905-908
 Chagas disease, 905-908
 cryptococcosis, in transplant patients, 725
 cryptosporidiosis, 873-897
 cysticercosis, 1011-1028
 dermatitis, 870
 effusion cytology in, 462
 filariasis, 977-1010
 giardiasis, 811-827
 granulomatous amebic encephalitis, 866-870
 keratitis, 870-871
 leishmaniasis, 909-922
 malaria, 941-956
 onchocerciasis, 1001-1002, 1005
 pneumocystosis, 312, 957-975
pneumonitis, 871
schistosomiasis, 1029-1039
sleeping sickness, 899-905
toxoplasmosis, 923-939
trypanosomiasis, 899-908
worms, 1041-1050
Parasitologic diagnosis, of African trypanosomiasis, 903-904
of American trypanosomiasis, 907-908
of filariasis. See under *Filariasis*.
of toxoplasmosis, 926-927
Paratope, definition of, 635-636
Parotid gland tumors, cytology in, 325-332
PASCAL, 59
Pathology services, payment for. See under *Payment*.
Patient identification/tracking, information systems for, 155-156
bar codes in, 234-235
Patient proximity testing systems, vs. hospital laboratories, 190-195
Payment, for pathology services, hospital-based, 1051-1063
 billable services, 1052-1054
 billing agent for, 1060-1061
 coding for, 1057-1060
 combination arrangements, 1055
 contracting principles in, 1052
 direct professional component billing, 1054
 fee schedule for, 1056-1057
 historical aspects of, 1051-1052
 percentage arrangements, 1054-1055
 salary arrangements, 1055
 stipend arrangements, 1055
 in Australia, 784-786
Pemphigus vulgaris, esophageal, cytology in, 414
Peptides, synthetic, in malaria immunodiagnosis, 949
Pericardial fluid cytology. See *Effusion cytology*.
Peritoneal fluid cytology. See *Effusion cytology*.
Personnel, for information system acquisition, 7-9
Phosphorylcholine assay, in filariasis diagnosis, 999-1000
Physician's office, information systems for, 239-249
 communication in, 243-244
 home monitoring and, 245
 image reports in, 242-243
 interfaces for, 239-240
 problems in, 247-248
 services provided by, 245, 247
 test performance in, 242
Phytohemagglutinin test, in kidney graft monitoring, 738
Pick programming language, 65

- Plasmacytoid lymphoma, cytology in, 491–492
- Plasmapheresis, in donor-specific antibody removal, 582
- Plasmodium*. See *Malaria, parasite of*.
- Pleomorphic adenoma, of salivary glands, cytology in, 326–327
- Pleural fluid cytology. See *Effusion cytology*.
- Pneumocystis carinii* infection. See *Pneumocystosis*.
- Pneumocystosis, clinical manifestations of, 959
- cytology in, 312
- diagnosis of, 957–975
- nonmorphologic, 970–971
 - specimen collection for, 961
 - specimen handling for, 961, 963
 - stains for, 963, 965–966, 970
- epidemiology of, 958–959
- in AIDS, 958–959
- in transplant patients, 724
- parasite of, 957–958
- pathophysiology of, 959
- treatment of, 959–960
- Pneumonia, cytology in, infectious, 311–312
- lipid, 312
- pneumocystic. See *Pneumocystosis*.
- Pneumonitis, *Acanthamoeba* in, 871
- Polycarbonate membrane, as concentration method, in filariasis diagnosis, 981–984
- Polymerase chain reaction, in
- pneumocystosis diagnosis, 971
 - in toxoplasmosis diagnosis, 935
- Polyvinyl alcohol fixative, for stool specimens, 833–834
- Practice guidelines, test request forms, 255–265
- Precipitins, gel-diffusion, in amebiasis, 851–852
- Pregnancy, toxoplasmosis in, 932–933
- Preservation, of stool specimens, 832–836
- formalin solutions for, 835–836
 - merthiolate iodine formalin for, 835
 - polyvinyl alcohol fixative for, 833–834
 - Schaudinn's fixative for, 834–835
 - sodium acetate-acetic acid-formalin fixative for, 836
- Primed lymphocyte test, in HLA typing, 513–514
- Printers, for bar codes, 229
- for information systems, 177–178
- Private antigens, in HLA class I, 517–518
- Programming languages. See *Languages, programming*.
- Prostate cancer, cytology in, 387–393
- cells found in, 389
 - complications of, 392–393
 - diagnostic value of, 391
 - errors in, 392
- indications for, 389, 391
- limitations of, 391–392
- pathology and, 388
- Prostate hyperplasia, cytology in, 389
- Prostatitis, cytology in, 392
- Protein(s), urinary, in kidney graft monitoring, 735–736
- Protein A, in donor-specific antibody removal, 582
- Pseudocyst, pancreatic, cytology in, 351–352
- Pulmonary cytology, 293–315
- bronchial brushing/washing in, 295
 - bronchoalveolar lavage in, 295–296
 - in adenocarcinoma, 301–306
 - in carcinoma, 454
 - in large-cell carcinoma, 309–310
 - in nonneoplastic disease, 310–313
 - in small-cell carcinoma, 306–309
 - in squamous cell carcinoma, 298–300
 - needle aspiration in, 297–298
 - of sputum, 294–295
- Pus, amebae detection in, 849–850
- Quality assurance, in Australia, 788
- Quantitative Buffy Coat apparatus, in malaria diagnosis, 950–951
- Radioimmunoassay, in American trypanosomiasis, 907
- in cyclosporine A monitoring, 674–677
- Radiology, in cysticercosis, 1015
- Radiotherapy, cell changes in, bladder, 380
- esophageal, 411–412
 - prostate, 392
- Recipient sera, for transplantation crossmatching, 607–608
- Red blood cell rosetting, in lymphocyte isolation, for crossmatch procedures, 606
- RED expert system, 143
- Reference laboratory, as hospital laboratory competitor, 190–192, 197
- combined with hospital laboratory. See *Hybrid laboratories*.
 - information systems for, 101–102
- Reflux esophagitis, cytology in, 406–407, 414–415
- Regulation. See *Laboratory regulation*.
- Rejection, of grafts. See *Graft rejection*.
- Renal cell carcinoma, cytology in, 382, 384, 386
- Reports, of test results, 171–185
- chart management and, 179–180
 - completed specimen, 174–175
 - cumulative, 89–96, 173–174
 - electronic inquiry of, 183–184

- examples of, 181–183
expert systems in, 144–146
for patient type, 180–181
grouping in, 178–179
in hybrid laboratories, 158–161
interim, 173
layout design for, 175–178
manual system for, 172
scheduling of, 179
sequencing in, 178–179
test-by-test, 174
turnaround time and, 190–191
voice, 184
- Request for proposal, for information systems, 21–26
- Respiratory distress syndrome, data in, expert systems for, 145
- Restriction fragment length polymorphism analysis, in HLA analysis, 515
- Rheumatoid disease, effusion cytology in, 462
- River blindness (onchocerciasis), 1001–1002, 1005
- Royal Australian College of General Practitioners, 789–790
- Royal College of Pathologists of Australasia, 788–789
- Salivary gland tumors, cytology in, 325–332, 334
carcinoma, 327, 329, 331
lymphoid infiltrates, 331
pleomorphic adenoma, 326–327
reliability of, 331–332
sialadenitis, 331
vs. normal tissue, 326
Warthin's tumor, 327
- Sarcoma, cytology in, effusion, 456–457, 460
granulocytic, 488–489
head and neck, 336
immunoblastic, 483–484
Kaposi's, 436
liver, 340, 342
- Schaudin's fixative, for stool specimens, 834–835
- Schistosomiasis, immunodiagnosis of, 1029–1039
commercial supplies for, 1036
cost estimates for, 1035–1036
enzyme-linked immunoelectrotransfer blot test in, 1034–1035
FAST-ELISA test in, 1031–1034
- Schwannoma, cytology in, 332–333
- Sclerosing adenosis, of breast, cytology in, 362
- Scrapings, from leishmaniasis lesion, 913–914
- Security systems, in information systems, 159, 242
- Serous cystadenoma, of pancreas, cytology in, 351
- Sheather's sugar solution, for oocyst concentration, 884
- Shell vial method, in cytomegalovirus infection, 728
- Sialadenitis, cytology in, 331
- Signet-ring carcinoma, in effusions, cytology in, 451
- Skin, *Acanthamoeba* infection of, 871
microfilariae detection in, 984–985
- Skin antibodies, crossmatch procedures with, 578, 625–629
- Skin autoantibodies, in crossmatch procedures, 629
- Skin test, for leishmaniasis, 919
- Small-cell carcinoma, cytology in, cervical, 279–280
effusion, 451, 454
lung, 306–309
metastatic to liver, 342
- Small intestine, specimen from, in giardiasis diagnosis, 819–820
- Smears, cervicovaginal. See *Gynecologic cytology*.
- SMR expert system, 146
- Sodium acetate-acetic acid-formalin fixative, for stool specimens, 836
- Sodium chloride solution, for oocyst concentration, 834
- Soft-tissue tumors, of head and neck, cytology in, 336
- Software. See also *Languages, programming*.
approval of, 36–37
bugs in, 15–16, 66–70
for bar codes, 236–237
for windowing, 127–128
inefficient, 47
licensing agreement for, 38
maintenance of, 37–38, 48
network-based, 48–49
operating system, 124–125
risks of, 30–31
- Specimen handling, expert system use in, 142–143
information systems for, 156–157
- Spleen, lymphocyte isolation from, for transplantation crossmatching, 605
- Sputum, cytology of, 294–295
examination of, in transplant patients, 724
induced, in pneumocystosis diagnosis, 961
- Squamous cell carcinoma, cytology in,
bladder, 371–372
cervical, human papillomavirus and, 281–282
preneoplastic/early neoplastic lesions and, 273–280

Squamous cell carcinoma (*Continued*)

cystic, 334
effusion, 451
esophageal, 409–410
lung, 298–300, 303
metastatic, 334, 341
vs. adenocarcinoma, 303

Squamous cell dysplasia, of esophagus,
cytology in, 413–414

Squamous intraepithelial lesions, cervical,
cytology in, 276–280

Staining, in parasitic disease diagnosis,
amebiasis, permanent, 843–845

temporary, 839–840
cryptosporidiosis, 884–886
filariasis, 979–981
pneumocystosis, 963, 965–966, 970
worms, 1049–1050

Stomach disorders, cytology in, 415–424

adenocarcinoma, 418–419
adenoma, 421–422
dysplasia, 421–422
epithelial repair, 415–417
gastritis, 415–416, 420, 423–424
histiocytic infiltration, 420
intestinal metaplasia, 417–418
lymphoma, 419, 422
neuroendocrine tumors, 422–423
stromal tumors, 424

Stones, urinary, cytology in, 380

Stool examination, in amebiasis, 831–845

concentration procedures for, 840–842
specimen collection for, 831–832
specimen number for, 832
specimen preservation for, 832–836
staining in, 842–844
temporary stains in, 838–839
temporary wet mounts in, 837–838
in cryptosporidiosis, 883–887
in cysticercosis, 1018–1020
in giardiasis, 818–819
parasite concentration in, 819, 884

String test, in giardiasis, 820

Stromal tumors, of stomach, cytology in, 424

T cell(s), cross reactive, in alloantigen
response, 539

cytotoxic, in kidney graft rejection, 737
regulation of, anti-idiotypic-like antibodies
and, 646–647

response of, to OKT3 therapy, 696–700,
704–706

T-cell antigen receptor, OKT3 monoclonal
antibody reaction with, 693–695

T-cell receptors, in alloantigen recognition,
540–541

Taenia solium infection. See *Cysticercosis*.
Tapeworm, pig. See *Cysticercosis*.

Teepol procedure, in filariae concentration,
982–983

Telecommunications, in information
systems, 49–50

Test order, entry of, in information systems,
96–97, 141–142
forms for, 255–265

Testicular tumors, cytology in, 393–394

Thyroglossal duct cyst, cytology in, 334

Thyroid gland disorders, cytology in, 317–
324

anaplastic carcinoma, 322

follicular adenoma, 318–319

follicular carcinoma, 319

Hashimoto's thyroiditis, 323–324

malignant lymphoma, 322–323

medullary carcinoma, 321

nodular goiter, 318

papillary carcinoma, 319–321

pitfalls in, 324

thyroiditis, 323–324

vs. normal tissue, 318

Tissue diagnosis, of granulomatous amebic
encephalitis, 867

Toluuidine blue O stain, in pneumocystosis
diagnosis, 965

Total testing process, expert systems in,
135–136, 141–146

Toxoplasmosis, 923–939

acquired, 925, 931–932

clinical types of, 925

congenital, 925, 932–933

diagnosis of, acquired, 931–932

antibody detection tests in, 928–931

antigen detection methods in, 931

commercial kits for, 931

congenital, 932–933

future prospects for, 935

immune status determination in, 931

in immunocompromised host, 934–935

in newborn infant, 933–934

ocular, 934

parasite identification in, 926–927

serologic techniques in, 927–931

specimen requirements for, 927–928

encephalitis in, 934–935

epidemiology of, 925–926

ocular, 925, 934

parasite of, identification of, 926–927

life cycle of, 923–925

transmission of, 923, 925

Transfusions, pretransplant, in donor-
specific antibody suppression, 582, 633–
634, 644–645

Transitional cell carcinoma, urinary cytology
in, 377, 381

Transplantation. See also specific organ.
alloimmunization in, anti-idiotypic-like an-
tibodies in, 633–632

monitoring of, 551–570

- aspiration cytology in, 743-744
 criteria for, 531
 crossmatch procedures in. See *Cross-match procedures*.
 cyclosporine A monitoring in, 671-691
 donor-specific antibodies in, 571-602
 exfoliative cytology in, 743-744
 graft rejection/survival and. See *Graft rejection*.
 histocompatibility testing, 734-735
 HLA immunogenetics in, 509-536
 immunologic heterogeneity and, 733-762
 in vitro testing in, 733-762
 incompatibility in, 533
 infection evaluation in, 715-731
 lymphocyte surface markers in, 739-741
 lymphokines in, 750-757
 non-HLA antigens in, 621-632
 renal, cytology in, 385-386
 selective mismatch results in, 565
 urinary sediment cytology in, 744-749
 zero mismatches in, 532-533
- TREACT expert system, 145
 Trichrome, in amebiasis diagnosis, 843-844
 Trophozoites, of *Entamoeba histolytica*, 829-830, 845-847
 of *Giardia*, 813, 816, 823
 Tsetse fly, in trypanosomiasis transmission, 901-902
 Tuberculosis, in transplant patients, 722
 Tubular cells, in urinary sediment, in transplant monitoring, 745-749
 Tumors, cytology of. See *Cytology*.
- Ulcerative colitis, cytology in, 431-434
 Ureter, cancer of, cytology in, 377
 Urinary cytology, 369-381
 as screening procedure, 374
 cells found in, 371-373
 diagnostic value of, 376-377, 380
 errors in, 380-381
 flow cytometry in, 381
 history of, 370
 in transplant recipient monitoring, 744-749
 indications for, 373-374
 Lewis antigens in, 381
 limitations of, 380
 pathology in, 370-371
 specimens for, 374-375
 Urine culture, in transplant patients, 723
 Urothelial cancer, cytology in. See *Urinary cytology*.
 Uterus, endometrial conditions of. See *Endometrium*.
- V-C-E smear, for gynecologic cytology, 272-273
 Vaginal smears. See *Gynecologic cytology*.
 Varicella-zoster virus infection, in transplant patients, 717, 721-722, 726
 Vascular endothelial cell antigen system, in graft rejection, 538, 577
 Victorian Pathology Services Accreditation Board (Australia), 782-783
 Viral capsid antigen test, 727
 Viral infections, cytology in, effusion, 462 lung, 311
 laboratory diagnosis of, 725-729
 of liver graft, vs. rejection, 657, 660-661
 Visceral leishmaniasis, diagnosis of, 911
 Voice mail, in result reporting, 243
- Warthin's tumor, cytology in, 327
 Water, contamination of, giardiasis transmission in, 817
 Western blot test (enzyme-linked immunoelectrotransfer blot test), in cysticercosis, 1016-1017
 in schistosomiasis, 1034-1035
 Wet mount, temporary, in amebiasis diagnosis, 837-838
 Wilms' tumor, cytology in, 384
 Word processing, 59-60
 Working Formulation, for lymphoproliferative disease, 471-472
 Workstations, for information systems. See under *Information systems*.
 World Health Organization, HLA nomenclature of, 516
 Worms and worm-like objects, 1041-1050
 clearing procedures for, 1048-1049
 examination of, 1044-1048
 fixation/handling of, 1043-1044
 flat, unsegmented, 1046-1047
 long, flat, unsegmented, 1047
 long, round, segmented, 1047-1048
 long, round, unsegmented, legless, 1045-1046
 staining of, 1049-1050
 types submitted, 1041-1043
 with legs, 1048
 Wright's stain, in pneumocystosis diagnosis, 966
Wuchereria bancrofti infection. See *Filariasis*.
- Zinc sulfate, for fecal specimen concentration, 840-842
 for oocyst concentration, 884